ADAG Adagene Inc.
$2.58▲ +3.61%
Healthcare
Other
Volume 189.2K
Avg Volume (10D) 306.0K
Key Metrics & Fundamentals
Market Cap
$173.23M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.30 - 4.85
% vs 50 MA
-17.81%
% vs 200 MA
-24.35%
RSI-14
45.4
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.06
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
GlobeNewswire · Oct 27, 2026 7:00 AM ET
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
MarketBeat · Oct 25, 2026 6:02 AM ET
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
MarketBeat · Oct 16, 2026 2:02 PM ET
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
GlobeNewswire · Oct 14, 2026 8:00 AM ET
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
GlobeNewswire · Sep 22, 2026 8:00 AM ET
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
GlobeNewswire · Sep 10, 2026 8:00 AM ET
Chardan Initiates Adagene at Buy With $9 Price Target
MT Newswires · Sep 10, 2026 6:59 AM ET
Adagene Receives Milestone Payment From Exelixis
MT Newswires · Sep 9, 2026 9:42 AM ET
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
GlobeNewswire · Sep 9, 2026 8:00 AM ET
Adagene to Participate in Three Upcoming Investor Conferences
GlobeNewswire · Aug 20, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.